Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Skye Bioscience Inc.

    NASDAQ: SKYE · Real-Time Price · USD
    2.07
    -0.05 (-2.36%)
    At close: Jun 17, 2025, 3:59 PM
    2.01
    -2.90%
    After-hours: Jun 17, 2025, 04:19 PM EDT
    -2.36%
    Bid 1.59
    Market Cap 64.14M
    Revenue (ttm) n/a
    Net Income (ttm) -11.12B
    EPS (ttm) -0.83
    PE Ratio (ttm) -2.49
    Forward PE -1.43
    Analyst Buy
    Ask 2.66
    Volume 124,974
    Avg. Volume (20D) 710,976
    Open 2.11
    Previous Close 2.12
    Day's Range 2.05 - 2.23
    52-Week Range 1.14 - 10.95
    Beta 1.67

    About SKYE

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SKYE
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SKYE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    4 weeks ago
    +14.97%
    Skye Bioscience shares are trading higher after th... Unlock content with Pro Subscription
    2 months ago
    +30.53%
    Skye Bioscience shares are trading higher after the company reported weight loss results from its Nimacimab and Tirzepatide preclinical obesity model.
    news image

    6 days ago · https://www.defenseworld.net

    Squarepoint Ops LLC Buys Shares of 13,546 Skye Bioscience, Inc. (NASDAQ:SKYE)

    Squarepoint Ops LLC bought a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exc...

    news image

    6 days ago · https://www.defenseworld.net

    Squarepoint Ops LLC Takes Position in Skye Bioscience, Inc. (NASDAQ:SKYE)

    Squarepoint Ops LLC acquired a new stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SE...

    news image

    3 weeks ago · zacks.com

    3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

    NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.

    news image

    4 weeks ago · proactiveinvestors.co.uk

    Arecor shares jump 10% on obesity drug partnership with Skye Bioscience

    Shares in Arecor Therapeutics PLC (AIM:AREC) rose 10% in morning trading after the company announced a new development deal with US biotech group Skye Bioscience to improve the formulation of a mid-st...

    news image

    4 weeks ago · proactiveinvestors.co.uk

    Arecor partners with Skye Bioscience to improve formulation of obesity drug

    Arecor Therapeutics PLC (AIM:AREC) has entered a development partnership with Skye Bioscience Inc (NASDAQ:SKYE), a US-based biotechnology group, to create a more concentrated formulation of an experim...

    news image

    1 month ago · seekingalpha.com

    Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

    Skye Bioscience, Inc. (NASDAQ:SKYE ) Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President & Chief Executive...

    news image

    2 months ago · seekingalpha.com

    A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

    Weight loss drug stocks like Novo Nordisk have dropped significantly lately. This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's nimaci...

    news image

    2 months ago · benzinga.com

    Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

    Skye Bioscience, Inc.  SKYE stock is trading higher on Tuesday with a strong session volume of 18.49 million compared to the average volume of 196.131k, as per data from Benzinga Pro.

    news image

    2 months ago · seekingalpha.com

    Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

    Skye Bioscience, Inc. (NASDAQ:SKYE ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President and Chief Exec...

    Add to Watchlist